According to the Zhitong Finance App, Longjin Pharmaceutical (002750.SZ) issued an announcement. According to preliminary estimates by the company's finance department, the audited net profit for 2023 is expected to be negative and operating income below 100 million yuan.

After the disclosure of the company's 2023 annual report, if the audited net profit for the most recent fiscal year is negative and operating income is less than 100 million yuan, or if the net profit for the most recent fiscal year is negative and operating income is less than 100 million yuan after retrospecting (the above net profit is before or after deducting non-recurring profit and loss; operating income shall be deducted from business income unrelated to the main business and income without commercial substance), according to section 9.3.1 of the “Shenzhen Stock Exchange Listed Stock Rules”, the company's stock trading may be subject to a delisting risk warning (with the word “*ST” before the stock abbreviation sample).